Eli Lilly and Innovent’s obesity drug mazdutide achieves positive Phase III results
Innovent has reported positive Phase III results for mazdutide, Eli Lilly’s next-generation obesity asset that Innovent is developing as part of a 2019 deal with the company where it secured the rights to the dual glucagon-like peptide-1 (GLP-1) glucagon receptor agonist.
Innovent has reported positive Phase III results for mazdutide, Eli Lilly’s next-generation obesity asset that Innovent is developing as part of a 2019 deal with the company where it secured the rights to the dual glucagon-like peptide-1 (GLP-1) glucagon receptor agonist.
What's Your Reaction?
